the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function

An Investigative Study on the Possible Effect of the Antiviral Inhibitors (Sofosbuvir and Daclatasvir) for Treatment of Hepatitis C Virus Infection in Cardiac Function

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03166943

Enrollment

130

Registered

2017-05-25

Start date

2017-05-10

Completion date

2020-12-31

Last updated

2020-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis

Brief summary

It has been known for many years that the heart and the liver are intimately related. There is a mutual interaction between the function of the heart and the liver and a broad spectrum of acute and chronic entities that affect both the heart and the liver. Chronic hepatitis C virus infection affects more than 3% (170 million) of the world's population.

Detailed description

Assessment of systolic function by echocardiography will be done to 100 hepatitis C virus infected patients who receive antiviral treatment (sofosbuvir and daclatasvir) by biplane simpson's method and by speckle tracking. Assessment of diastolic function by echocardiography to 30 hepatitis C virus infected patients who will not receive antiviral treatment, by left atrium volume , mitral inflow pattern , tissue doppler annular early and late diastolic velocities .

Interventions

PROCEDURESystolic function by echocardiography

Echocardiography for evaluation of systolic function: * by biplane Simpson's method. * by speckle tracking:

PROCEDUREDiastolic function by echocardiography

Echocardiography for evaluation of diastolic function: * Left atrial Volume * Mitral Inflow Patterns * Pulsed wave Doppler * Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns. * Tissue Doppler Annular Early and Late Diastolic Velocities * Pulsed wave tissue doppler imaging * Primary measurements include the systolic , early diastolic, and late diastolic velocities.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. patients on continuous regimen (Sofosbuvir and daclatasvir) for 3 months 2. normal baseline trans thoracic echocardiography 3. normal Electrocardiography

Exclusion criteria

1 - Diabetes mellitus, hypertension and chronic kidney disease. 2- Hepatitis C virus patients with any baseline Electrocardiography abnormality. 3- Patients with underlying any structural heart disease.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of patients with ventricular dysfunction	3 months	The percentage of ventricular dysfunction in hepatitis C virus patients who received antiviral treatment in comparison with patients with hepatitis C virus who didn't receive antiviral treatment

Countries

Egypt

Contacts

Primary ContactYehia Kishk, MD

ytkishk2002@yahoo.com00201011030011

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026